Olinvyk

(Oliceridine)

ApprovedSmall molecule

Olinvyk is a small molecule that works as a Mu Opioid Receptor Agonist.[2] It is being used across 11 indications, with its most advanced program in Approved.[1]

Olinvyk is one of 90 small molecule programs targeting Pain. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Chronic PainActive, not recruiting

Nausea and VomitingActive, not recruiting

StrabismusActive, not recruiting

Colorectal SurgeryCompleted

Chronic Post-Surgical PainEnrolling by invitation

Thyroid DiseaseActive, not recruiting

Chronic PainApproved

Active, not recruiting

Nausea and VomitingApproved

Active, not recruiting

StrabismusPreclinical

Active, not recruiting

Colorectal SurgeryApproved

Completed

Chronic Post-Surgical PainApproved

Enrolling by invitation

Thyroid DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

224 competitors in Nausea and Vomiting

#DrugCompanyPhaseTrials

Olinvyk

TTrevena Inc.

Approved

1 2

Aloxi

AAvyxa

Preclinical

27 3

Alfenta

Alnylam Pharmaceuticals

Preclinical

1 4

Ramosetron

Astellas

Preclinical

15 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

7 6

Phenergan

BBassett Healthcare

Preclinical

5 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Haldol

DDePuy Orthopaedics

Preclinical

3 9

Adriamycin

GGynecologic Oncology Group

Preclinical

2 10

Cytoxan

BBaxter Healthcare Corporation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/ANot yet recruiting

Strabismus

NCT07112157

Q4 2026

N/ARecruiting

Postoperative Analgesia

NCT06990893

Q3 2027

N/ANot yet recruiting

Nausea

NCT07479446

Clinical

Trials by Indication[1]

Oliceridine3 trials

Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy

Completed·TTrevena Inc.·Phase 3·NCT02815709·418 enrolled

Analgesic Effect and Safety of Oliceridine and Oxycodone in Vitrectomy

Not yet recruiting·HHenan Provincial People's Hospital·N/A·NCT07097038·120 enrolled

Oliceridine in Patients With Acute Burn Injuries

Completed·UUniversity of Tennessee·Phase 4·NCT05465226·31 enrolled

Postoperative Analgesia2 trials

Comparison of the Analgesic Effect of Oliceridine Versus Morphine or Sufentanil for Postoperative Analgesia in Lumbar Surgeries: a Randomized Control Trial

Recruiting·—·N/A·NCT06990893·90 enrolled

Clinical Study of G Protein Biased Μ - Opioid Receptor Agonist Oliceridine for Optimizing Postoperative Analgesia Under General Anesthesia

Not yet recruiting·HHenan Provincial People's Hospital·N/A·NCT06668298·150 enrolled

Tracheal Intubation1 trial

Oliceridine Dose for Tracheal Intubation Hemodynamic Elevation: Up-and-Down Trial

Completed·SShiyou Wei·N/A·NCT07154979·58 enrolled

Complication1 trial

Intravenous Oliceridine and Opioid-related Complications

Completed·TThe Cleveland Clinic·Phase 4·NCT04979247·111 enrolled

Gastrointestinal Endoscopy1 trial

Respiratory Safety of Oliceridine During Sedated Gastrointestinal Endoscopy

Completed·SShiyou Wei·N/A·NCT07187765·508 enrolled

11 more indications

Oliceridine Fumarate1 trial

the Efficacy and Safety of Oliceridine Fumarate Injection for Acute Pain After Abdominal Surgery

Not yet recruiting·XXiangya Hospital of Central South University·Phase 4·NCT06530563·606 enrolled

Dexmedetomidine1 trial

Dexmedetomidine-Enhanced PCIA After Lobectomy in Nicotine-Dependent Patients

Completed·SShenyang Sixth People's Hospital·Phase 4·NCT07306702·102 enrolled

Nausea1 trial

Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery

Not yet recruiting·XXuanwu Hospital, Beijing·N/A·NCT07479446·174 enrolled

Nausea and vomiting1 trial

Oliceridine on Postoperative Nausea and Vomiting in Gynecological Laparoscopic Surgery

Recruiting·YYanYing Xiao·Phase 4·NCT07026162·96 enrolled

Abdominoplasty1 trial

Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty

Completed·TTrevena Inc.·Phase 3·NCT02820324·407 enrolled

Efficacy and Safety1 trial

To Evaluate the Efficacy and Safety of Tegileridine and Oliceridine Injections in the Treatment of Postoperative Pain

Completed·YYuwei Qiu·Phase 4·NCT06458400·75 enrolled

Randomised Controlled Trial1 trial

Effects and Safety of Oliceridine in Anesthesia Induction:A Randomised Controlled Trial

Completed·—·N/A·NCT07372209·120 enrolled

Strabismus1 trial

Efficacy of Oxalidine and Sufentanil in Strabismus Correction

Not yet recruiting·HHenan Provincial People's Hospital·N/A·NCT07112157·290 enrolled

Chronic Post-surgical Pain1 trial

The Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Thoracoscopic Lobectomy

Enrolling by invitation·TTianjin Medical University General Hospital·Approved·NCT07018375·320 enrolled

Colorectal Surgery1 trial

Effect of Oliceridine Analgesia on Postoperative Nause and Vomiting in Laparoscopic Colorectal Surgery: A Randomized Trial

Completed·PPeking University First Hospital·Approved·NCT06411665·252 enrolled

Cough1 trial

Oliceridine vs Sufentanil for Cough During General Anesthesia Induction: A Randomized Controlled Trial

Not yet recruiting·SShiyou Wei·Approved·NCT07660380·62 enrolled

Regulatory

FDA Approval Timeline[4]

Oct 30, 2020

OLINVYK

NDA NDA210730

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Oliceridine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oliceridine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oliceridine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA210730). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Olinvyk. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Trevena Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Mu Opioid Receptor Agonist[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TTrevena Inc.

Patent Landscape[5]

Patent Cliff

Mar 23, 2032

Earliest patent expiration — generic entry possible after this date

Patent #Expires

11931350Mar 23, 2032

9642842Mar 23, 2032

8835488Mar 23, 2032

9309234Mar 23, 2032

11077098Mar 23, 2032

Olinvyk

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q3 2027

Trials by Indication[1]

Oliceridine3 trials

Postoperative Analgesia2 trials

Tracheal Intubation1 trial

Complication1 trial

Gastrointestinal Endoscopy1 trial

Oliceridine Fumarate1 trial

Dexmedetomidine1 trial

Nausea1 trial

Nausea and vomiting1 trial

Abdominoplasty1 trial

Efficacy and Safety1 trial

Randomised Controlled Trial1 trial

Strabismus1 trial

Chronic Post-surgical Pain1 trial

Colorectal Surgery1 trial

Cough1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News